In a phase III trial (AURA3), osimertinib was linked to a significantly longer progression‐free survival (PFS), compared to standard chemotherapy with platinum and pemetrexed, as second‐line treatment for T790M mutation‐positive advanced NSCLC (median PFS 10.1 vs. 4.4 months).11 Therefore, in the case of treatment resistance to first‐ or second‐generation EGFR‐TKIs, after testing for the EGFR T790M mutation, osimertinib treatment is recommended as second‐line treatment for T790 mutation‐positive patients. This evidence concerns the gene EGFR and non-small cell lung carcinoma.